Biovitrum AB And Syntonix Pharmaceuticals, Inc. Enter Agreement For The Joint Development And Commercialization Of Recombinant Factor IX For The Treatment Of Hemophilia

STOCKHOLM, Sweden--(BUSINESS WIRE)--Jan. 23, 2006--Biovitrum AB, Sweden, and Syntonix Pharmaceuticals, Inc., USA, have entered into a co-development and commercialization agreement for Syntonix' long-acting, recombinant Factor IX product for Hemophilia B ("FIX:Fc"). Under the terms of the agreement, Syntonix receives an initial collaboration fee and Biovitrum makes an equity investment in Syntonix.

Back to news